Moran Mieron
Chief Tech/Sci/R&D Officer bij UROGEN PHARMA LTD.
Actieve functies van Moran Mieron
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
UROGEN PHARMA LTD. | Chief Tech/Sci/R&D Officer | - | - |
Pluristem Ltd.
Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The private company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Chief Tech/Sci/R&D Officer | - | - |
Loopbaan van Moran Mieron
Eerdere bekende functies van Moran Mieron
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
QUOIN PHARMACEUTICALS, LTD. | Chief Tech/Sci/R&D Officer | 19-02-2014 | 15-05-2016 |
Opleiding van Moran Mieron
Technion-Israel Institute of Technology | Doctorate Degree |
Statistieken
Internationaal
Israël | 4 |
Verenigde Staten | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 3 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Sectoraal
Health Technology | 3 |
Commercial Services | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
UROGEN PHARMA LTD. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Pluristem Ltd.
Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The private company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Commercial Services |
Cellect Biotechnology Ltd.
Cellect Biotechnology Ltd. Medical SpecialtiesHealth Technology Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel. | Health Technology |
- Beurs
- Insiders
- Moran Mieron
- Ervaring